The Manufacturers Life Insurance Company Takes $71,000 Position in Design Therapeutics, Inc. (NASDAQ:DSGN)

The Manufacturers Life Insurance Company bought a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 13,221 shares of the company’s stock, valued at approximately $71,000.

Other large investors also recently modified their holdings of the company. Bank of New York Mellon Corp increased its stake in Design Therapeutics by 2.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 118,110 shares of the company’s stock valued at $396,000 after purchasing an additional 2,868 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Design Therapeutics by 44.5% during the second quarter. Acadian Asset Management LLC now owns 583,160 shares of the company’s stock valued at $1,952,000 after buying an additional 179,614 shares during the last quarter. American Century Companies Inc. bought a new stake in shares of Design Therapeutics during the second quarter worth about $71,000. Dimensional Fund Advisors LP raised its holdings in shares of Design Therapeutics by 119.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 80,953 shares of the company’s stock worth $271,000 after acquiring an additional 44,098 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Design Therapeutics in the 2nd quarter valued at about $81,000. 56.64% of the stock is currently owned by institutional investors.

Design Therapeutics Stock Performance

DSGN stock opened at $6.25 on Wednesday. The business has a 50-day simple moving average of $5.83 and a two-hundred day simple moving average of $4.95. The company has a market capitalization of $353.88 million, a P/E ratio of -7.35 and a beta of 1.86. Design Therapeutics, Inc. has a 52-week low of $2.24 and a 52-week high of $7.77.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.